- Home
- IVP vs VIRX Comparison
IVP vs VIRX Comparison
Compare IVP & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- VIRX
- Stock Information
- Founded
- IVP 2020
- VIRX 2007
- Country
- IVP United States
- VIRX United States
- Employees
- IVP N/A
- VIRX N/A
- Industry
- IVP Diversified Commercial Services
- VIRX Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- VIRX Health Care
- Exchange
- IVP Nasdaq
- VIRX Nasdaq
- Market Cap
- IVP 7.3M
- VIRX 6.3M
- IPO Year
- IVP 2023
- VIRX N/A
- Fundamental
- Price
- IVP $0.19
- VIRX $0.21
- Analyst Decision
- IVP
- VIRX Buy
- Analyst Count
- IVP 0
- VIRX 4
- Target Price
- IVP N/A
- VIRX $5.00
- AVG Volume (30 Days)
- IVP 1.5M
- VIRX 3.8M
- Earning Date
- IVP 11-13-2024
- VIRX 11-13-2024
- Dividend Yield
- IVP N/A
- VIRX N/A
- EPS Growth
- IVP N/A
- VIRX N/A
- EPS
- IVP N/A
- VIRX N/A
- Revenue
- IVP $17,054,777.00
- VIRX N/A
- Revenue This Year
- IVP N/A
- VIRX N/A
- Revenue Next Year
- IVP N/A
- VIRX N/A
- P/E Ratio
- IVP N/A
- VIRX N/A
- Revenue Growth
- IVP 6.12
- VIRX N/A
- 52 Week Low
- IVP $0.18
- VIRX $0.13
- 52 Week High
- IVP $50.00
- VIRX $1.31
- Technical
- Relative Strength Index (RSI)
- IVP 36.55
- VIRX 60.26
- Support Level
- IVP $0.20
- VIRX $0.14
- Resistance Level
- IVP $0.22
- VIRX $0.19
- Average True Range (ATR)
- IVP 0.02
- VIRX 0.03
- MACD
- IVP 0.01
- VIRX 0.01
- Stochastic Oscillator
- IVP 17.81
- VIRX 74.38
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.